Public domain

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Delayed-release Tablets in the United States

Retrieved on: 
Tuesday, September 3, 2019

The agreement also includes rights to posaconazole 40mg/mL oral suspension which Par intends to launch in the coming months.

Key Points: 
  • The agreement also includes rights to posaconazole 40mg/mL oral suspension which Par intends to launch in the coming months.
  • "Paris pleased to provide patients and providers with access to a lower-cost treatment through our launch of the authorized generic version of Noxafil," said Domenic Ciarico, Executive Vice President & Chief Commercial Officer, Sterile & Generics at Endo.
  • Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA.
  • Because these statements reflect Endo's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties.

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Delayed-release Tablets in the United States

Retrieved on: 
Tuesday, September 3, 2019

The agreement also includes rights to posaconazole 40mg/mL oral suspension which Par intends to launch in the coming months.

Key Points: 
  • The agreement also includes rights to posaconazole 40mg/mL oral suspension which Par intends to launch in the coming months.
  • "Paris pleased to provide patients and providers with access to a lower-cost treatment through our launch of the authorized generic version of Noxafil," said Domenic Ciarico, Executive Vice President & Chief Commercial Officer, Sterile & Generics at Endo.
  • Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA.
  • Because these statements reflect Endo's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties.

Visiongain Report Researches Growth Opportunities Within the $424bn Generic Drugs Market

Retrieved on: 
Wednesday, August 21, 2019

Asia-Pacific held 31% of the generic drugs market in 2018.

Key Points: 
  • Asia-Pacific held 31% of the generic drugs market in 2018.
  • In this brand new 246-page report you will receive 66 tables and 84 figures all unavailable elsewhere.
  • The 246-page report provides clear detailed insight into the generic drugs market.
  • To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/generic-drugs-market-forecast-2019-202...
    Generic Drugs Market forecasts from 2019-2029 by Regional and National Market:
    Profiles and generic drugs revenue forecasts from 2019-2029 of these selected leading companies:

Visiongain Report Researches Growth Opportunities Within the $424bn Generic Drugs Market

Retrieved on: 
Wednesday, August 21, 2019

Asia-Pacific held 31% of the generic drugs market in 2018.

Key Points: 
  • Asia-Pacific held 31% of the generic drugs market in 2018.
  • In this brand new 246-page report you will receive 66 tables and 84 figures all unavailable elsewhere.
  • The 246-page report provides clear detailed insight into the generic drugs market.
  • To request sample pages from this report please contact Sara Peerun at [email protected] or refer to our website: https://www.visiongain.com/report/generic-drugs-market-forecast-2019-202...
    Generic Drugs Market forecasts from 2019-2029 by Regional and National Market:
    Profiles and generic drugs revenue forecasts from 2019-2029 of these selected leading companies:

The global motion sickness drugs market at a CAGR of almost 4% during the forecast period

Retrieved on: 
Monday, August 19, 2019

Global Motion Sickness Drugs Market: About this market

Key Points: 
  • Global Motion Sickness Drugs Market: About this market
    Motion sickness drugs are pharmaceutical agents that are used to treat nausea and vomiting caused due to motion sickness.
  • However, nonpharmacological countermeasures to treat motion sickness, the launch of generics, side effects associated with motion sickness drugs may hamper the growth of the motion sickness drugs industry over the forecast period.
  • Global Motion Sickness Drugs Market: Overview
    The global motion sickness drugs market is predominantly served by the use of generic drugs that are available both as prescription and OTC drugs.
  • This demand for over-the-counter (OTC) will lead to the expansion of the global motion sickness drugs market at a CAGR of almost 4% during the forecast period.

Canadians benefitting from substantially lower generic drug prices

Retrieved on: 
Wednesday, August 14, 2019

Over the past decade, the pan-Canadian Pharmaceutical Alliance (pCPA) has made a concerted effort to lower generic drug prices in Canada.

Key Points: 
  • Over the past decade, the pan-Canadian Pharmaceutical Alliance (pCPA) has made a concerted effort to lower generic drug prices in Canada.
  • The most recent agreement between the pCPA and the Canadian Generic Pharmaceutical Alliance (CGPA) effectively closes the gap between Canadian and international prices.
  • From 2007 to 2018, prices of selected oral generic drugs in Canada have fallen more than prices in comparable countries, decreasing by almost 60%.
  • "I'm thrilled that our efforts to lower drug prices are paying off for all Canadians.

Global Anti-epileptic Drugs for Pediatrics Market to Surpass US$ 1.6 Billion by 2026

Retrieved on: 
Thursday, August 8, 2019

Key Trends and Analysis of the Anti-epileptic Drugs for Pediatrics Market:

Key Points: 
  • Key Trends and Analysis of the Anti-epileptic Drugs for Pediatrics Market:
    Key players have gained approval for new medicines for the treatment of epilepsy in recent years.
  • Approval and launch of new drugs is expected to support the anti-epileptic drugs for pediatrics market growth over the forecast period.
  • Furthermore, launch of generic drugs is expected to support growth in adoption rate for anti-epileptic drugs due to lower price of generics.
  • The global anti-epileptic drugs for pediatrics market is expected to exhibit a CAGR of 7.9% over the forecast period.

Japan Generic Drug Market Trends, Share, Size, Growth, Opportunity and Forecasts, 2011-2018 & 2019-2024

Retrieved on: 
Monday, July 15, 2019

DUBLIN, July 15, 2019 /PRNewswire/ -- The "Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 15, 2019 /PRNewswire/ -- The "Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024" report has been added to ResearchAndMarkets.com's offering.
  • Japan represents the world's eighth biggest market for generic drugs in terms of value.
  • The landscape of the japan generic drug market, however, has changed noticeably over the last decade.
  • The Japanese government has identified growth of the country's generic drug market as imperative to Japan's long-term economic health.

Amring Pharmaceuticals Announces the Launch of Two Valued Pharmaceutical Generics

Retrieved on: 
Tuesday, June 25, 2019

Mesalamine Suppositories, 1000 mg, a generic version of Canasa Suppositories, an aminosalicylate indicated for the treatment of active ulcerative proctitis.

Key Points: 
  • Mesalamine Suppositories, 1000 mg, a generic version of Canasa Suppositories, an aminosalicylate indicated for the treatment of active ulcerative proctitis.
  • Amring anticipates adding at least two additional products to its commercial portfolio this year.
  • Amring Pharmaceuticals is a privately-held generic pharmaceutical company active in global markets geared to supplying unique and specialized products.
  • The company is part of the global Amring Pharmaceuticals business and is partnered with well-established global biopharmaceutical companies.

Resulticks Welcomes Sophie Pibouin as Executive VP of Sales of the Americas

Retrieved on: 
Tuesday, June 18, 2019

Sophie Pibouin brings a global perspective, deep understanding of the market and unparallel expertise in propelling business growth.

Key Points: 
  • Sophie Pibouin brings a global perspective, deep understanding of the market and unparallel expertise in propelling business growth.
  • In her new role, Sophie will lead efforts to expand Resulticks' U.S. footprint and identify new opportunities for accelerated growth.
  • "I am delighted to be joining a rapidly growing organization that is delivering a holistic solution to its users," said Sophie Pibouin, Resulticks Executive VP of Sales of the Americas.
  • Prior to joining Resulticks, Sophie was the Worldwide Sales Leader at IBM Watson.